Can Eptifibatide Rewrite the Nstemi Story? (Eptifibatide Vs. Standard Care for Nstemi: A 5-Year Analysis of Major Adverse Cardiovascular Events)

Can Eptifibatide Rewrite the Nstemi Story? (Eptifibatide Vs. Standard Care for Nstemi: A 5-Year Analysis of Major Adverse Cardiovascular Events) Publisher Pubmed

Kalhor P ; Nowrouzi P ; Ghahari P ; Mehrani M

Source: Catheterization and Cardiovascular Interventions Published:2025

Abstract

Background: Coronary artery disease (CAD) is a leading cause of death worldwide. Among acute coronary syndromes, non-ST-elevation myocardial infarction (NSTEMI) poses a higher long-term risk than ST-elevation myocardial infarction (STEMI). Eptifibatide, a glycoprotein IIb/IIIa inhibitor, is used during percutaneous coronary intervention (PCI) to prevent clots, but its long-term effects in NSTEMI patients remain unclear. Aims: This study assesses the impact of Eptifibatide on major adverse cardiac events (MACE) and survival in NSTEMI patients undergoing PCI. Methods: A retrospective cohort study of NSTEMI patients treated between 2015 and 2022 at Tehran Heart Center. Patients were grouped based on whether they received Eptifibatide. MACE outcomes were tracked during hospitalization and 1 year later. Statistical adjustments were made for baseline differences. Results: Among 5309 patients, 12% received Eptifibatide. There were no significant differences between groups in MACE (17.2% vs. 15.6%) or survival (HR 0.97, p = 0.901). Conclusion: Eptifibatide showed no significant effect on MACE or survival in NSTEMI patients undergoing PCI. Further research is needed to explore its role in high-risk subgroups. © 2025 Elsevier B.V., All rights reserved.

Style	Citing Format
MLA	Kalhor P, et al.. "Can Eptifibatide Rewrite the Nstemi Story? (Eptifibatide Vs. Standard Care for Nstemi: A 5-Year Analysis of Major Adverse Cardiovascular Events)." Catheterization and Cardiovascular Interventions, vol. , no. , 2025, pp. -.
APA	Kalhor P, Nowrouzi P, Ghahari P, Mehrani M (2025). Can Eptifibatide Rewrite the Nstemi Story? (Eptifibatide Vs. Standard Care for Nstemi: A 5-Year Analysis of Major Adverse Cardiovascular Events). Catheterization and Cardiovascular Interventions, (), -.
Chicago	Kalhor P, Nowrouzi P, Ghahari P, Mehrani M. "Can Eptifibatide Rewrite the Nstemi Story? (Eptifibatide Vs. Standard Care for Nstemi: A 5-Year Analysis of Major Adverse Cardiovascular Events)." Catheterization and Cardiovascular Interventions , no. (2025): -.
Harvard	Kalhor P et al. (2025) 'Can Eptifibatide Rewrite the Nstemi Story? (Eptifibatide Vs. Standard Care for Nstemi: A 5-Year Analysis of Major Adverse Cardiovascular Events)', Catheterization and Cardiovascular Interventions, (), pp. -.
Vancouver	Kalhor P, Nowrouzi P, Ghahari P, Mehrani M. Can Eptifibatide Rewrite the Nstemi Story? (Eptifibatide Vs. Standard Care for Nstemi: A 5-Year Analysis of Major Adverse Cardiovascular Events). Catheterization and Cardiovascular Interventions. 2025;():-.
BibTex	@article{ author = {Kalhor P and Nowrouzi P and Ghahari P and Mehrani M}, title = {Can Eptifibatide Rewrite the Nstemi Story? (Eptifibatide Vs. Standard Care for Nstemi: A 5-Year Analysis of Major Adverse Cardiovascular Events)}, journal = {Catheterization and Cardiovascular Interventions}, volume = {}, number = {}, pages = {-}, year = {2025} }
RIS	TY - JOUR AU - Kalhor P AU - Nowrouzi P AU - Ghahari P AU - Mehrani M TI - Can Eptifibatide Rewrite the Nstemi Story? (Eptifibatide Vs. Standard Care for Nstemi: A 5-Year Analysis of Major Adverse Cardiovascular Events) JO - Catheterization and Cardiovascular Interventions VL - IS - SP - EP - PY - 2025 ER -

Science Communicator Platform

Authors

Abstract